Sites today have to be agile in order to deliver on unexpected targets and respond rapidly to changes.
UCB’s new antibody facility will be the group’s first large-scale biotechnology production centre. NNE Pharmaplan was in charge of managing the EUR 172 million project.
The pharmaceutical industry is under growing pressure and faces changes, also in manufacturing. What constitutes a successful manufacturing site in the new pharma reality?
Niels Guldager, Senior Technology Partner within biopharmaceuticals, assesses the top ten trends characterising the ever-changing and rapid-growing biotech industry right now.
Engineer with life science experience? Help us develop and deliver complex solutions to demanding customers. And go home smarter every day.
What does the term "new pharma reality" mean to you? Gert Moelgaard, VP for Strategic Development at NNE Pharmaplan gives you his - and our customers' - perspective.
© 2013 NNE Pharmaplan